AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancerThe European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) for the treatment of germline BRCA-mutated HER2-negative advanced Share XAZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancerhttps://pharmaphorum.com/news/az-and-msds-lynparza-gets-eu-nod-for-hard-to-treat-breast-cancer/
Real-world data unlocks Ibrance ok in male breast cancerThe FDA has expanded the use of Pfizer’s Ibrance to include use in breast cancer in men based Share XReal-world data unlocks Ibrance ok in male breast cancerhttps://pharmaphorum.com/news/real-world-data-unlocks-ibrance-ok-in-male-breast-cancer/
AZ signs multi-billion cancer R&D deal with Daiichi SankyoAstraZeneca is to raise $3.5 billion to fund a global development and marketing collaboration with Daiichi Sankyo, for Share XAZ signs multi-billion cancer R&D deal with Daiichi Sankyohttps://pharmaphorum.com/news/az-signs-multi-billion-cancer-rd-deal-with-daiichi-sankyo/
UK gets early access to Roche’s breast cancer immunotherapyHard on the heels of an FDA approval for Roche’s Tecentriq and Celgene’s Abraxane for triple-negative breast cancer Share XUK gets early access to Roche’s breast cancer immunotherapyhttps://pharmaphorum.com/news/uk-early-access-roches-breast-cancer-immunotherapy/
How T-cell therapy saved my lifeJudy Perkins’ stage 4 cancer was eradicated after she joined a clinical trial for T-cell therapy. She shares Share XHow T-cell therapy saved my lifehttps://pharmaphorum.com/views-analysis-patients/how-t-cell-therapy-saved-my-life/
Roche gets first checkpoint inhibitor OK in breast cancerRoche’s Tecentriq was the third PD-1/PD-L1 inhibitor to reach the market but is the first in class to Share XRoche gets first checkpoint inhibitor OK in breast cancerhttps://pharmaphorum.com/news/roche-gets-first-checkpoint-inhibitor-ok-in-breast-cancer/
Roche seeks Kadcyla boost to fend off Herceptin biosimilarsAs biosimilar competition to Herceptin ramps up, Roche is looking to bolster its position in HER2-positive breast cancer Share XRoche seeks Kadcyla boost to fend off Herceptin biosimilarshttps://pharmaphorum.com/news/roche-seeks-new-kadcyla-indication/
FDA approves Samsung/Merck & Co’s Herceptin biosimilarThe FDA has approved a new biosimilar of Roche’s breast cancer drug Herceptin, from Samsung Bioepis and Merck Share XFDA approves Samsung/Merck & Co’s Herceptin biosimilarhttps://pharmaphorum.com/news/fda-approves-samsung-merck-cos-herceptin-biosimilar/
Lilly’s Verzenios approved by NICENICE has published draft guidance that now recommends Eli Lilly’s breast cancer drug Verzenios for use on the Share XLilly’s Verzenios approved by NICEhttps://pharmaphorum.com/news/lillys-verzenios-approved-nice/
